Search Results

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe.

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A)1 in patients with C9ORF72 amyotrophic lateral sclerosis (ALS)2.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.

Calibre Scientific is pleased to announce the acquisition of AIT France, a manufacturer and distributor of innovative consumables for analytical chemistry and chromatography.